{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:32:54Z","timestamp":1792510374880,"version":"4.5.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Predicting the treatment efficacy of programmed cell death protein 1 (PD-1) inhibitors is crucial for guiding optimal treatment plans and preventing unnecessary complications for cancer patients. We aimed to develop a prediction model using clinical and body composition parameters to identify gastric cancer (GC) patients who would respond to chemotherapy plus PD-1 antibody.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Clinical data of GC patients treated with chemotherapy plus PD-1 antibody (immunotherapy cohort, n = 120) or chemotherapy alone (chemotherapy cohort, n = 82) following surgical resection were reviewed as the training set. Patients treated with chemotherapy plus PD-1 antibody at an external center were included as the validation set (n = 43). Tumor regression grade (TRG) was recorded and classified as TRG0\/1 or TRG2\/3 during analysis. Body composition parameters were assessed on computed tomography images at the third lumbar vertebral level using the SliceOmatic software. Univariate and multivariate analyses were performed to identify parameters associated with TRG0\/1, and then a logistic regression model was developed to stratify patients into the good and poor response groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the training set, clinical and body composition parameters between the immunotherapy cohort and chemotherapy cohort were similar. Skeletal muscle radiation attenuation (SMRA), neutrophil-to-lymphocyte ratio (NLR), and weight loss were associated with TRG0\/1 in the immunotherapy cohort. Subcutaneous adipose tissue index (SATI) and metastasis were identified in the chemotherapy cohort. A logistic regression model was developed to stratify immunotherapy cohort patients into two response groups with an area under the receiver operating characteristic curve (AUC) value of 0.728. In the immunotherapy cohort, patients stratified as good responders showed a higher TRG0\/1 rate (37\/55, 67.3%) than poor response patients (18\/65, 27.7%, <jats:italic>p<\/jats:italic> &amp;lt; 0.001) and had better overall survival (<jats:italic>p<\/jats:italic> = 0.001). In the external validation set, patients stratified using the clinical model as good responders also showed a higher TRG0\/1 rate (14\/18, 77.8%) than poor response patients (9\/25, 36.0%, <jats:italic>p<\/jats:italic> = 0.012).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The prediction model consisting of SMRA, NLR, and weight loss could help identify GC patients who respond well to chemotherapy plus PD-1 antibody.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1685592","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T05:35:00Z","timestamp":1759815300000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical and body composition parameters as predictors of response to chemotherapy plus PD-1 inhibitor in gastric cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Chenfei","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P. J.","family":"van Dijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinling","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liting","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuekun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengfan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenggang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander S.","family":"Rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven W. M.","family":"Olde Damink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001474","article-title":"Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020","volume":"134","author":"Cao","year":"2021","journal-title":"Chin Med J (Engl)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2021.02.05","article-title":"Screening for gastric cancer in China: Advances, challenges and visions","volume":"33","author":"Fan","year":"2021","journal-title":"Chin J Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S0140-6736(14)62038-9","article-title":"Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2)","volume":"385","author":"Allemani","year":"2015","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.21.01862","article-title":"Low programmed death-ligand 1-expressing subgroup outcomes of first-line immune checkpoint inhibitors in gastric or esophageal adenocarcinoma","volume":"40","author":"Zhao","year":"2022","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"152881","DOI":"10.1016\/j.prp.2020.152881","article-title":"High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features","volume":"216","author":"Liu","year":"2020","journal-title":"Pathol Res Pract"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-021-01195-4","article-title":"Optimized PD-L1 scoring of gastric cancer","volume":"24","author":"Schoemig-Markiefka","year":"2021","journal-title":"Gastric Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-020-00664-y","article-title":"A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases","volume":"34","author":"Huang","year":"2021","journal-title":"Mod Pathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0219","article-title":"Determinants of response and intrinsic resistance to PD-1 blockade in microsatellite instability-high gastric cancer","volume":"11","author":"Kwon","year":"2021","journal-title":"Cancer Discov"},{"key":"B14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-021-03294-3","article-title":"Sarcopenia: imaging assessment and clinical application","volume":"47","author":"Chianca","year":"2022","journal-title":"Abdom Radiol (NY)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12484","article-title":"Prognostic role of body composition parameters in gastric\/gastroesophageal junction cancer patients from the EXPAND trial","volume":"11","author":"Hacker","year":"2020","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e318216f449","article-title":"Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: A summary of 480 cases","volume":"253","author":"Becker","year":"2011","journal-title":"Ann Surg"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/nu13082493","article-title":"The utility of body composition assessment in nutrition and clinical practice: an overview of current methodology","volume":"13","author":"Holmes","year":"2021","journal-title":"Nutrients"},{"key":"B19","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1038\/s41467-023-40024-3","article-title":"Adipose tissue and skeletal muscle wasting precede clinical diagnosis of pancreatic cancer","volume":"14","author":"Babic","year":"2023","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2012.06.011","article-title":"Cancer cachexia: mediators, signaling, and metabolic pathways","volume":"16","author":"Fearon","year":"2012","journal-title":"Cell Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12633","article-title":"Cancer cachexia and skeletal muscle atrophy in clinical studies: what do we really know","volume":"11","author":"Dolly","year":"2020","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00624-w","article-title":"The interplay of immunology and cachexia in infection and cancer","volume":"22","author":"Baazim","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnesp.2021.06.029","article-title":"CT-based assessment of body composition and skeletal muscle in melanoma: A systematic review","volume":"45","author":"Youn","year":"2021","journal-title":"Clin Nutr ESPEN"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12193","article-title":"The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021","volume":"41","author":"Wang","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"B25","article-title":"Predictive biomarkers and new developments of immunotherapy in gastric cancer: a 2023 update","volume":"13","author":"Nie","year":"2023","journal-title":"Am J Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12538","article-title":"Body composition is prognostic and predictive of ipilimumab activity in metastatic melanoma","volume":"11","author":"Chu","year":"2020","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3631","article-title":"Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non-small cell lung cancer","volume":"10","author":"Nishioka","year":"2021","journal-title":"Cancer Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1061044","article-title":"Body composition parameters for predicting the efficacy of neoadjuvant chemotherapy with immunotherapy for gastric cancer","volume":"13","author":"Lin","year":"2022","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1081762","article-title":"Circulating neutrophils activated by cancer cells and M2 macrophages promote gastric cancer progression during PD-1 antibody-based immunotherapy","volume":"10","author":"Zhou","year":"2023","journal-title":"Front Mol Biosci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41467-021-20935-9","article-title":"Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors","volume":"12","author":"Valero","year":"2021","journal-title":"Nat Commun"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01055","article-title":"Changes in nutritional status impact immune cell metabolism and function","volume":"9","author":"Alwarawrah","year":"2018","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","article-title":"Cancer-associated cachexia","volume":"4","author":"Baracos","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2593","article-title":"Myosteatosis in a systemic inflammation-dependent manner predicts favorable survival outcomes in locally advanced esophageal cancer","volume":"8","author":"Gabiatti","year":"2019","journal-title":"Cancer Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/MCO.0b013e328338236e","article-title":"The interaction between adipokines, diet and exercise on muscle insulin sensitivity","volume":"13","author":"Stefanyk","year":"2010","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190450","article-title":"Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia","volume":"218","author":"Rupert","year":"2021","journal-title":"J Exp Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.10.010","article-title":"Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity","volume":"24","author":"Flint","year":"2016","journal-title":"Cell Metab"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1038\/s41467-017-02358-7","article-title":"TNFalpha blockade overcomes resistance to anti-PD-1 in experimental melanoma","volume":"8","author":"Bertrand","year":"2017","journal-title":"Nat Commun"},{"key":"B39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.7150\/jgen.5260","article-title":"Molecular heterogeneities of adipose depots - potential effects on adipose-muscle cross-talk in humans, mice and farm animals","volume":"2","author":"Komolka","year":"2014","journal-title":"J Genomics"},{"key":"B40","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.ccell.2022.05.006","article-title":"Exercise-induced engagement of the IL-15\/IL-15Ralpha axis promotes anti-tumor immunity in pancreatic cancer","volume":"40","author":"Kurz","year":"2022","journal-title":"Cancer Cell"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-021-00559-1","article-title":"Practical prediction model of the clinical response to programmed death-ligand 1 inhibitors in advanced gastric cancer","volume":"53","author":"Noh","year":"2021","journal-title":"Exp Mol Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41392-024-01932-y","article-title":"Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-008927","article-title":"Development and interpretation of a pathomics-driven ensemble model for predicting the response to immunotherapy in gastric cancer","volume":"12","author":"Han","year":"2024","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1685592\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T05:35:01Z","timestamp":1759815301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1685592\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2025.1685592"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1685592","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"article-number":"1685592"}}